Clinical trials: Isolated Cervical Dystonia
Isolated/Primary Dystonia That Affects More Than One Region of the Body
An Observational Study of Individuals With Isolated Dystonia
This is an observational study in individuals with isolated (or primary) dystonia that involves more than one body region. The purpose of the study is to collect detailed information to help your physician and other researchers…
- Trial name
- NCT07111663
- Where
- 29 sites in United States
- Volunteers
- 200 people
- Sponsor
- Vima Therapeutics
Dystonia
A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia
Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia.
- Trial name
- NCT07304089
- Testing
- VIM0423
- Where
- 45 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Vima Therapeutics
Cervical Dystonia
Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center trial of two doses of daxibotulinumtoxinA (DAXI) for injection (high-dose; low-dose in adult subjects with isolated (primary) cervical dystonia…
- Trial name
- ASPEN-1 (NCT03608397)
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 75 sites in United States, Austria and 7 more
- Volunteers
- 301 people
- Sponsor
- Revance Therapeutics, Inc.
Cervical Dystonia
Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)
Phase 3, open-label, multi-center trial to evaluate the long-term safety, efficacy, and immunogenicity of up to four continuous treatment cycles of daxibotulinumtoxinA (DAXI) for injection.
- Trial name
- ASPEN-OLS (NCT03617367)
- Testing
- daxibotulinumtoxinA for injection
- Where
- 65 sites in United States, Austria and 7 more
- Volunteers
- 357 people
- Sponsor
- Revance Therapeutics, Inc.